Dicyclomine is NOT Appropriate for Fibromyalgia Treatment
Dicyclomine (Bentyl) should not be used for fibromyalgia. This anticholinergic medication is FDA-approved exclusively for gastrointestinal smooth muscle spasm in irritable bowel syndrome, not for fibromyalgia pain or other core symptoms 1.
Why Dicyclomine Doesn't Work for Fibromyalgia
Wrong Mechanism of Action
Dicyclomine functions as an antimuscarinic agent that relieves gastrointestinal smooth muscle spasm through anticholinergic effects 1. Fibromyalgia pain arises from central sensitization and altered neurotransmitter processing—mechanisms completely unrelated to smooth muscle spasm 2. The drug has no activity on the central pain pathways that drive fibromyalgia symptoms.
No Evidence Base
The most comprehensive and recent guidelines for fibromyalgia management make no mention of dicyclomine or any antispasmodic agents for fibromyalgia treatment:
- The 2022 VA/DoD guidelines explicitly state there is insufficient evidence to recommend for or against antispasmodics, but this applies only to gastrointestinal symptoms in patients with irritable bowel syndrome—not fibromyalgia pain 3
- The 2017 EULAR guidelines do not include dicyclomine in any treatment recommendations 4
- Multiple systematic reviews of fibromyalgia pharmacotherapy from 2001-2025 consistently omit dicyclomine entirely 5, 6, 7, 8, 2, 9
Significant Safety Concerns
Dicyclomine carries substantial risks that make it particularly inappropriate for fibromyalgia patients:
- Anticholinergic side effects occur in 61% of patients: dry mouth (33%), dizziness (29%), blurred vision (27%), drowsiness (9%), and weakness (7%) 1
- CNS effects including confusion, disorientation, hallucinations, and psychosis can occur 1
- Thrombosis risk with IV administration, though this is less relevant for oral use 10
- These side effects would worsen the cognitive dysfunction ("fibro fog") and fatigue already present in fibromyalgia
What Actually Works for Fibromyalgia
Evidence-Based Pharmacological Options
When medication is indicated, use agents with proven efficacy 3, 4:
First-line pharmacotherapy:
Second-line considerations:
- Amitriptyline (insufficient evidence but expert opinion supports trial) 3
- Low-dose cyclobenzaprine (5.6 mg sublingual at bedtime) specifically targets nonrestorative sleep and has recent phase 3 trial support 11
Non-Pharmacological Approaches (Preferred)
The strongest recommendation in fibromyalgia management is exercise 4. The treatment algorithm should prioritize:
- Initial management: Patient education plus aerobic exercise, strength training, or meditative movement therapies (yoga, tai chi) 3, 4, 12
- Add if inadequate response: Cognitive-behavioral therapy or mindfulness-based therapies 3, 4
- Consider pharmacotherapy only for: Severe pain, significant sleep disturbance, or comorbid mood disorders 4, 12
What to Avoid
- NSAIDs (guidelines suggest against for fibromyalgia pain) 3
- Long-term opioids (strong recommendation against) 3
- Muscle relaxants (should be avoided per German guidelines) 12
- Antispasmodics like dicyclomine (no role in fibromyalgia)
Clinical Pitfall
If a patient with fibromyalgia has been prescribed dicyclomine, investigate whether they have comorbid irritable bowel syndrome. Up to 60% of fibromyalgia patients have IBS, and dicyclomine may have been appropriately prescribed for the IBS component—not the fibromyalgia 8. However, even for IBS in fibromyalgia patients, the evidence for antispasmodics remains insufficient 3.